Sironax Ltd. has disclosed new NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors potentially useful for the treatment of Parkinson’s disease, multiple sclerosis, traumatic brain injury, diabetic neuropathy, Alzheimer’s disease, Huntington’s disease, hereditary neuropathies, and stroke.